Oxford BioTherapeutics and Boehringer Ingelheim enter collaboration to discover novel antibody targets in cancer

Oxford BioTherapeutics (OBT) and Boehringer Ingelheim (BI) today announce a new alliance focused on the discovery of novel cancer antibody targets that OBT will identify with the help of its OGAP® discovery platform.

Under the collaboration OBT will validate certain targets it has discovered that are compatible with targeting by various antibody drug formats across a range of cancer indications. Following completion of these activities, BI will have the exclusive right to develop and commercialize antibody products for selected programs.

OBT will receive an undisclosed upfront payment and FTE funding for its activities under the collaboration, and will be eligible for certain milestone payments upon the achievement of specified discovery, development and commercialization milestones, as well as royalties on sales of any resulting products.

Christian Rohlff, CEO of OBT, commented, “Selecting the right target is fundamental for the successful development of a first in class antibody product drug and we are delighted to collaborate with a company of the calibre of BI in this exciting area of cancer antibody development.”